All treatments
Treatment
Rixathon 500 mg concentrate for solution for infusion clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedPhase II and Phase III (Integrated)
Evaluation of Glucocorticoids plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA vasculitis: A Prospective, randomized, controlled, double-blind study
This study looks at new treatments for IgA vasculitis (IgAV), focusing on using specific medications (Rituximab or Rixathon) with standard steroid treatment. The aim is to see if these combinations can help patients get into remission and stay there, reducing the need for steroids.
For: Patients with a diagnosis of IgAV according to Chapel Hill Consensus Conference definitions. Patients will require having a biopsy-proven diagnosis of IgAV.France - Ongoing, recruitingTherapeutic use (Phase IV)
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
This study looks at ways to help a medicine called Asfotase Alfa (STRENSIQ®) work better for people with Hypophosphatasia. Sometimes the body fights this medicine, so the study tests other treatments to stop that and improve how well the medicine works.
For: HYPOPHOSPHATASIAFrance